MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP today announced the closing of a $233 million healthcare fund, MVM IV. The fund is MVM’s fourth and largest raised to date.

MVM IV is investing in medical companies, principally in Europe and the United States. The fund invests broadly across the healthcare field including in technologies, therapeutics, medical devices and healthcare IT and across all stages of development from early-stage private deals to quoted companies. Investment size will generally range from $15 million up to $30 million per portfolio company.

“We have had a very positive response from investors and we are delighted with the group of investors we have been able to attract,” said Dr Stephen Reeders, Managing Partner. “We believe the fund raising was helped by several factors including MVM’s compelling investment strategy, extensive track record, the strength of the team and our transatlantic presence with offices in London and Boston.”

MVM IV LP

MVM IV LP
Fund

Downloads

DownloadPress Release

Latest News

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera

MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.

Heptares and Allergan Announce Global R&D and Commercialization Partnership

Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

bioTheranostics Raises $32 Million in a Private Equity Financing & Announces Spinout From bioMérieux

bioTheranostics, Inc., a leader in molecular diagnostics for cancer, has announced that it has closed a $32 million financing led by MVM Life Science Partners.